P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Metastatic Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
S 81694 Plus Paclitaxel in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
- Status
- COMPLETED
- Phase
- PHASE1
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
- Status
- COMPLETED
- Phase
- PHASE3
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
- Status
- WITHDRAWN
- Phase
- NA
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1